The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gene-specific outcomes in patients with Lynch syndrome treated by immune checkpoint blockade for advanced cancer.
 
Violaine Randrian
No Relationships to Disclose
 
Oliver Artz
No Relationships to Disclose
 
Mohammad Abbass
No Relationships to Disclose
 
Emily Harrold
No Relationships to Disclose
 
Michael Foote
Honoraria - Axiom Healthcare Strategies; Horizon CME; OncLive
Consulting or Advisory Role - Abbott Laboratories; Bristol Meyers Squibb; Genzyme
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Abbvie; Agenus; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Regeneron; Roche/Genentech; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Diana Mandelker
No Relationships to Disclose
 
Ying Liu
Consulting or Advisory Role - Myriad Genetics
Research Funding - Artios (Inst); AstraZeneca (Inst); Repare Therapeutics (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Myriad Genetics
 
Marie Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Kidney Cancer Association; Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Alicia Latham
No Relationships to Disclose
 
Yonina Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Consulting or Advisory Role - Abbvie; Revolution Medicines
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; National Institutes of Health (NIH)/National Cancer Institute (NCI); Squeri Grant for Drug Development; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Luis Diaz
Leadership - Epitope Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Neophore; Seer; Zydecom
Consulting or Advisory Role - Neophore; Seer; Zydecom
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Benoit Rousseau
Consulting or Advisory Role - Bayer (Inst); Neophore; Roche (Inst)
Speakers' Bureau - Bayer; Gilead Sciences
Research Funding - Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; SERVIER
 
Zsofia Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Neurogene (I); Novartis (I); Optos (I); Outlook Therapeutics (I); Regeneron (I)
Patents, Royalties, Other Intellectual Property - Intellectual property rights (SOPHiA Genetics) (Inst)
Other Relationship - JCO Precision Oncology, Associate Editor; UpToDate, Section Editor